Genetic and Metabolic Determinants of Plasminogen Activator Inhibitor 1 (PAI-1) in Tunisian Type 2 Diabetes Patients

Background: PAI-1 (plasminogen activator inhibitor-1) is a powerful regulator of fibrinolysis and plasma level is high in type 2 diabetes and cardio-vascular disease, which is determined by genetic polymorphisms in PAI-1 gene and environmental factors. The aim of the study was to examine the determinants of plasma PAI-1 Ag level among type 2 diabetes patients. Methods: 491 Tunisian type 2 diabetes patients had clinical evaluation (weight, high, BMI, Waist Circumference), laboratory investigations including FBG Hb1Ac, cholesterol, triglyceride;HDL-cholesterol was done;plasma PAI-1 antigen level was done with ELISA;&minus;675 4G/5G and &minus;844 G/A polymorphisms of PAI-1 gene was done by PCR-ASA and PCR-RFLP respectively. Results: The mean age for our patients was 58.3 ± 10.5 years;sex-ratio = 0.92;mean PAI-1 level was 34.6 ± 21.3 ng/ml. We didn’t find correlation between PAI-1 level and BMI, but we have found significant correlation between PAI-1 and waist circumference (p = 0.032), most enhanced in men (P = 0.002), T2D patients who have FBG > 11 mmol/l had PAI-1 Ag level higher than those who have FBG P = 0.034), but no difference found between T2D with high Hb1Ac > 8% and those with Hb1Ac < 8%, significant correlation was seen between PAI-1 level and LDL-cholesterol (P = 0.05), high correlation between PAI-1 Ag level and &minus;675 4G/5G polymorphism genotype was seen, 4G/4G carriers had the highest PAI-1 level, 4G/5G had intermediary level and 5G/5G had the lowest level (P &minus;844G/A polymorphism genotypes. Using multiple variable linear regression analysis, the independent factor associated with plasma PAI-1 level was &minus;675 4G/5G polymorphism (regression coefficient β = 4.6, P Conclusion: the present study identifies &minus;675 4G/5G not &minus;844 G/A polymorphism of PAI gene as the principal determinant of plasma PAI-1 level in Tunisian T2D patients, the android fat distribution, dyslipidemia and hyperglycemia play a modest role in this variation.

Overexpression of hepatic plasminogen activator inhibitor type 1 mRNA in rabbits with fatty liver

INTRODUCTIONPlasminogen activator inhibitor type 1 ( PAI-I ), an approximately Mr 50000 glycoprotein, is the major physiological inhibitor of plasminogen activators. It is not only the priming factor for atherosclerosis and coronary thrombosis[1-3] , but also participates in the genesis of chronic hepatitis and liver fibrosis[4-11] . However, there has been no available report yet about the research of hepatic PAl-1 gene expression in hyperlipidemia and fatty liver. The present study aimed to explore the change of hepatic PAl-1 mRNA and its plasma activity by means of animal model.

INVESTIGATION OF THROMBOMODULIN AND PLASMINOGEN ACTIVATOR INHIBITOR TYPE-I IN PREGNANCY INDUCED HYPERTENSION AND ITS CLINICAL SIGNIFICANCE

Objective. To measure the circulating levels of thrombomodulin (TM) and plasminogen activator inhibitor type- I (PAI- I) in women with pregnancy induced hypertension (PIH). Methods. Blood samples were drawn from 97 pregnant women in their third trimester, grouped as 25 mild PIH,26 moderate PIH,22 severe PIH and 24 normotensive healthy pregnant women for determining levels of TM by ELISA,PAI- I by colorimetric assay methods, and creatinine (Cr) in serum by biochemical method. Results. Circulating levels of TM, PAI- I and TM/Cr ratio increased with increasing severity of PIH. There were no significant differences between mild and normotensive pregnant women. The parameters were significantly changed in the moderate and severe PIH groups. Conclusion. TM and PAI- I may serve as meaningful clinical markers for the assessment of the endothelial damage in PIH, which is very important in evaluating and following the development of PIH.

THE INCREASE IN PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 EXPRESSION BY STIMULATION OF ACTIVATORS FOR PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS IN HUMAN ENDOTHELIAL CELLS

Objective.To investigate the effect of peroxis ome proliferator-activated recept ors(PPARs )activators on plasminogen activator inhibitor ty pe-1(PAI-1)expression in human umbilical vein e ndothelial cells and the possi-ble mechanism.Methods.Human umbilical vein endothelial ce lls(HUVECs )were obtained from normal fetus,and cul-tured conventionally.Then the HUVECs were exposed to test agents(linolenic acid,linoleic acid,oleic acid,stearic acid and prostaglandin J 2 respectively)in varying concentrations with fresh media.RT -PCR and ELISA were applied to determine the expression of PPARs and PAI-1in HUVECs.Results.PPARα,PPARδand PPARγmRNA were detected by using RT-PCR in HUVECs.Treatment of HUVECs with PPARαand PPARγactivators---linolenic acid,linoleic acid,oleic acid and prostaglandin J 2 respectively,but not with stearic a cid could augment PAI-I mRNA expression and protein secretion in a concentration-dependent manner.However,the mRNA expressions of 3subclasses of PPAR with their activators in HUVECs were not changed compared w ith controls.Conclusion.HUVECs express PPARs.PPARs activators may increase PAI-1expression in ECs,but the underlying mechanism remains uncle ar.Although PPARs expression was not enhanced after stimulated by their activators in ECs,the role of functionally active PPARs in regulating PA I-1expression in ECs needs to be further investigated by using transient gen e transfection assay.

Roles of tissue plasminogen activator and its inhibitor in proliferative diabetic retinopathy

AIMTo investigate the role of tissue plasminogen activator (t-PA) and plasminogen activator inhibitor (PAI) in proliferative diabetic retinopathy (PDR) and to discuss the correlations among t-PA, PAI and vascular endothelial growth factor (VEGF) expressions.

Expression and prognostic value of plasminogen activator inhibitor type 1 in node-negative breast cancer

Objective： To investigate the expressions of plasminogen activator inhibitor type 1 （PAl-1）, C-erbB-2, VEGF and Ki-67 by immunohistostaining and then to evaluate the prognostic value of PAl-1 in node-negative breast cancer. Methods： The study included a retrospective series of 62 female patients with axillary lymph node-negative breast cancer. Expressions of PAl-1, C-erbB-2, VEGF and Ki-67 were determined by immunohistostaining on formalin-fixed paraffin-embedded tissue sections from these patients after a median follow-up of 69 months （range 22-117 months）. Correlations with well known clinicopathologic factors were assessed and multivariate survival analyses were performed. Results： High PAl-1 level was positively associated with high histologic grade of the tumors. Disease-free survival （DFS） was significantly shorter for the patients with moderate to intensive expression of PAl-1 than for those with negative （χ^2 = 25.46, P 〈 0.001; χ^2 = 23.07, P 〈 0.001） to mild expression （χ^2 = 19.75, P 〈 0.001; χ^2 = 17.40, P 〈 0.001）. Although on univariate analysis of the prognostic factors, tumor size, location of primary tumor and age as well as expressions of PAl-1, VEGF and Ki-67 were all significantly prognostic factors for DFS （P 〈 0.05）, PAl-1 was the only independent prognostic factor on multivariate analysis （P 〈 0.0001; hazard ratio [HR], 4.041; 95% confidence interval [CI], 1.928-8.468）. Conclusion： These results of the current study indicate that intermediate or high expression of PAl-1 represents a strong and independent unfavorable prognostic factor for the development of recurrence or metastases in axillary node-negative breast cancer.

Association of plasminogen activator inhibitor-1 4G/5G promoter polymorphism with recurrent cerebral infarction in China’s North Jiangsu Province

BACKGROUND： Many international studies have shown that plasminogen activator inhibitor-1 （PAl-l） 4G/5G promoter polymorphism does not increase the risk for cerebral infarction. OBJECTIVE： Using PCR methodology and agarose electrophoresis to detect PAI-1 4G/5G promoter polymorphism in patients with recurrent cerebral infarction in the North Jiangsu Province of China, and to compare results with healthy subjects and patients with first-occurrence cerebral infarction in the same region. DESIGN, TIME AND SETTING： Non-randomized, concurrent, control trial. A total of 122 cerebral infarction patients were admitted to Xuzhou Medical College Hospital＇s Department of Neurology and Xuzhou Central Hospital＇s Department of Neurology between July 2003 and August 2006. PARTICIPANTS： The patients consisted of 63 males and 59 females, aged （62 ± 10） years. They were divided into first-occurrence （n = 58） and recurrence （n = 64） groups. In addition, 50 healthy subjects that underwent physical examination in the outpatient department, including 26 males and 24 females, aged （60 ±12） years, were selected as controls. METHODS AND MAIN OUTCOME MEASURES： PAl-1 4G/5G promoter polymorphism was detected and analyzed using PCR methodology and agarose electrophoresis. RESULTS： Significant differences were determined in terms of genotypic frequency and allele frequency of PAI-1 4G/5G promoter polymorphism, in patients with first-occurrence or recurrent cerebral infarction, when compared with healthy subjects （P 〈 0.05）. There was, however, no significant difference between the first-occurrence and recurrence groups （P 〉 0.05）. CONCLUSION： PAl- 1 4G/5G promoter polymorphism is genetic risk factor for cerebral infarction in China. However, it may be associated with recurrence of cerebral infarction in patients from the North Jiangsu Province of China.

THE EFFECT OF RADIX SALVIAE MILTIORRHIZAE ON THE INHIBITORY ACTIVITY OF VASCULAR SMOOTH MUSCLE CELLS TO THE PLASMINOGEN ACTIVATORS SECRETED BY ENDOTHELIAL CELLS

Cultured porcine endothelial cells (EC) produce and secrete plasminogenactivators (PA). If the serum free media incubated by vascular smooth muscle cells(SMC-CM) were mixed with the same media incubated by endothelial cells (EC-CM),the PA activities of the latter decreased significantly. Cocultivation of EC with SMC alsoresulted in a significant decrease (70.7%) of PA activities produced by EC. Sodiumdodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) analysis of SMC-CMfollowed by reverse fibrin autography demonstrated that the PA inhibitor had a molecularweight of 49000-62000. In this study we also investigated the effect of a Chinese herbalmedicine-Radix Salviae Miltiorrhizae (RSM) on the inhibitory activity of SMC. The re-sults showed that RSM significantly decreased the inhibitory activity of SMC against thePA secreted by EC.

Comment on roles of tissue plasminogen activator and its inhibitor in proliferative diabetic retinopathy

Dear Sir,We congratulate Wu et al for their study entitled＂Roles of tissue plasminogen activator and its inhibitor in proliferative diabetic retinopathy＂.The authors investigated the effects of tissue plasminogen activator（t-PA）and plasminogen activator inhibitor（PAI）in the pathogenesis of proliferative diabetic retinopathy（PDR）.The authors reported that t-PA and PAI are involved in the pathogenesis of PDR.

EFFECTS OF TGF-β_1 ON THE EXPRESSION OF PLASMINOGEN ACTIVATOR INHIBITOR TYPE 1 IN CULTURED HUMAN RENAL INTERSTITIAL FIBROBLASTS

Objective To investigate the effects of transforming growth factor-β1 (TGF-β1 ) on the expression of plasminogen activator inhibitor type 1 (PAI-1 ) mRNA in renal interstitial fibrosis in vitro. Methods Human renal interstitial fibroblasts were isolated and cultured in vitro. The cells wers stimulated by TGF-β1 with different concentration (0 to 10ng/ml ) at different time (0 to 48h). The expression of PAI-1 mRNA was assayed by RT-PCR. Results TGF-β1, had dose-dependent and time-dependent effects on the expression of PAI-1 mRNA in renal interstitial fibroblasts. Conclusion TGF-β1 may partic- ipate in renal fibrosis with inducing the expression of PAI-1 mRNA in renal fibroblasts and affecting the synthesis and degradation of extracellular matrix (ECM).

Study on Effect of Different Dosages of Ligustrazine on Level of Plasminogen Activator Inhibitor-1 Activity in Type 2 Diabetes Mellitus Patients

Objective: To observe the effect of different dosages of ligustrazine (LG) on the level of plasminogen activator inhibitor-1 (PAI-1) activity in patients with type 2 diabetes mellitus. Methods: Ninety cases of type 2 diabetes mellitus inpatients were selected, and randomly divided into LG small dosage group (SDG), LG large dosage group (LDG) and control group. The 120 mg LG, 400 mg LG and normal saline 250 ml were given through intravenous dripping respectively, once daily, 20 days as one treatment course. Before and after treatment, all the patients had their fasting blood taken for PAI-1 and tissue plasminogen activator (t-PA) assessment test to perform the comparative study. Results:Seventy-three out of the 90 patients completed the observation course, the PAI-1 activity of three groups after treatment all lowered compared with that before treatment, and the difference between groups was also significant (all P<0. 01). After treatment the PAI-1 level of SDG and LDG of LG were all markedly lowered (all P<0. 01), the LDG's lowering was more evident than that of SDG, and comparison between these two groups of patients showed significant difference (P<0. 01). Although in the control group there was some difference between before and after treatment, it was not so significant like the above-mentioned two groups (P = 0. 0140). No adverse reaction occurred in the 3 groups during the observation period. Conclusion:LG could safely and effectively lower type 2 diabetes mellitus patient's plasma PAI-1 activity level, and LDG of LG proved to be particularly effective.

血清和胸腔积液PAI-1、TGF-β、VEGF、IL-6在结核性胸膜炎胸膜纤维化患者中的变化及临床意义

目的探讨血清和胸腔积液纤溶酶原激活剂抑制物-1(PAI-1)、转化生长因子-β(TGF-β)、血管内皮生长因子(VEGF)、白细胞介素-6(IL-6)在结核性胸膜炎胸膜纤维化患者中的变化及临床意义。方法选取2020年7月至2023年7月该院收治的103例结核性胸膜炎胸膜纤维化患者作为研究对象,治疗2周后,根据糖皮质激素治疗疗效将其分为显效组、非显效组。比较两组治疗前及治疗1、2周后血清和胸腔积液PAI-1、TGF-β、VEGF、IL-6水平。采用Spearman相关分析血清和胸腔积液PAI-1、TGF-β、VEGF、IL-6水平与疗效的相关性。治疗2周后血清PAI-1、TGF-β、VEGF、IL-6水平与胸腔积液中该指标水平之间进行Pearson相关分析。绘制受试者工作特征曲线分析治疗1、2周后血清和胸腔积液PAI-1、TGF-β、VEGF、IL-6水平对结核性胸膜炎胸膜纤维化患者疗效的预测价值。结果两组治疗1、2周后血清和胸腔积液PAI-1、TGF-β、VEGF、IL-6水平低于治疗前,显效组治疗1、2周后血清和胸腔积液PAI-1、TGF-β、VEGF、IL-6水平低于非显效组,差异有统计学意义(P<0.05)。治疗1、2周后血清和胸腔积液PAI-1、TGF-β、VEGF、IL-6水平与疗效呈负相关(P<0.05)。治疗2周后血清PAI-1、TGF-β、VEGF、IL-6水平和胸腔积液PAI-1、TGF-β、VEGF、IL-6水平呈正相关(r=0.761、0.783、0.812、0.741,均P<0.05)。治疗1、2周后血清和胸腔积液各指标联合检测的曲线下面积(AUC)大于其单独指标的AUC(P<0.05)。结论结核性胸膜炎胸膜纤维化患者血清和胸腔积液PAI-1、TGF-β、VEGF、IL-6水平与疗效有关,血清及胸腔积液PAI-1、TGF-β、VEGF、IL-6联合检测的预测价值较好,能够为临床干预提供参考依据。

超声衰减参数联合血清PAI-1和ALT水平评估代谢相关脂肪性肝病患者肝脂肪变性程度的价值分析

目的分析超声衰减参数(UAP)联合血清纤溶酶原激活物抑制物1(PAI-1)和丙氨酸氨基转移酶(ALT)水平评估代谢相关性脂肪性肝病(MAFLD)患者肝脂肪变性程度的效能。方法2019年3月~2022年12月我院诊治的112例MAFLD患者均接受肝穿刺活检,所有受试者接受iLivTouch瞬时弹性成像检测UAP,采用ELISA法检测血清PAI-1水平,应用受试者工作特征(ROC)曲线分析UAP联合血清PAI-1和ALT水平评估MAFLD患者肝脂肪变性程度的效能。结果在112例MAFLD患者中,经肝组织病理学检查发现肝脂肪变1级(轻度)45例,2级(中度)42例和3级(重度)25例;重度肝脂肪变患者BMI、血清TC、TG和LDL-C水平分别为(32.6±2.4)kg/m^(2)、(6.6±0.9)mmol/L、(4.6±1.4)mmol/L和(4.0±0.9)mmol/L,显著高于中度患者【分别为(27.6±1.9)kg/m^(2)、(5.8±0.8)mmol/L、(3.5±0.9)mmol/L和(3.5±0.7)mmol/L,P<0.05】或轻度患者【分别为(24.1±0.9)kg/m^(2)、(5.1±0.7)mmol/L、(2.2±0.7)mmol/L和(3.0±0.5)mmol/L,P<0.05】,而血清HDL-C水平为(1.2±0.2)mmol/L,显著低于中度【(1.4±0.2)mmol/L,P<0.05】或轻度患者【(1.4±0.2)mmol/L,P<0.05】;重度组UAP、血清PAI-1和ALT水平分别为(312.7±32.6)dB/m、(36.5±4.2)mg/mL和(72.1±7.4)U/L,显著高于中度组【分别为(284.2±30.1)dB/m、(28.1±3.4)mg/mL和(36.3±4.1)U/L,P<0.05】或轻度组【分别为(257.4±26.4)dB/m、(20.4±2.4)mg/mL和(23.7±2.5)U/L,P<0.05】;ROC曲线分析显示,UAP联合血清PAI-1和ALT水平评估重度肝脂肪变性的曲线下面积(AUC)、特异度和敏感度分别为0.914(95%CI:0.883~0.990)、89.6%和93.3%,其特异度显著优于单一指标预测(P<0.05)。结论应用UAP联合血清PAI-1和ALT水平预测MAFLD患者严重肝脂肪变性有良好的评估价值,可为临床诊治提供参考依据。

PAI-1、Hcy水平与妊娠合并心脏病患者妊娠结局的相关性分析

目的探讨纤溶酶原激活物抑制物-1(PAI-1)、同型半胱氨酸(Hcy)水平与妊娠合并心脏病患者妊娠结局的相关性。方法选取2020年1月至2023年1月我院收治的80例合并心脏病的孕妇作为研究组,另选取同期产检健康孕妇80例作为对照组,比较研究组与对照组PAI-1、Hcy水平。将研究组患者根据妊娠结局分为妊娠不良组22例和妊娠良好组58例,比较两组临床资料、三酰甘油(TG)、总胆固醇(TC)、PAI-1、Hcy水平;相关性采用Spearman秩相关分析检验;多因素分析采取二元Logistics回归分析;绘制ROC曲线,分析血清PAI-1、Hcy水平预测不良妊娠结局的价值。结果研究组PAI-1、Hcy水平显著高于对照组(P<0.05);妊娠不良组和妊娠良好组年龄、产次、孕周、分娩孕周、心脏病类型、心功能分级、TC、TG比较差异无统计学意义(P>0.05),妊娠不良组PAI-1、Hcy水平显著高于妊娠良好组(P<0.05);妊娠合并心脏病患者血清PAI-1、Hcy水平与不良妊娠结局呈正相关(P<0.05);多因素Logistic回归分析显示,PAI-1及Hcy为妊娠合并心脏病患者不良妊娠结局的显著影响因素;经ROC分析发现PAI-1、Hcy水平可用于妊娠合并心脏病患者不良妊娠结局的预测,曲线下面积为0.810、0.817,联合预测曲线下面积为0.918。结论妊娠合并心脏病患者血清PAI-1、Hcy水平显著增加孕妇不良妊娠结局发生率,上述指标与不良妊娠结局显著相关,其水平是不良妊娠结局的影响因素,并可用于不良妊娠结局预测,联合预测价值更高。

TAT、TM、PIC、t-PAIC与重型血液毒毒蛇咬伤中毒患者DIC的相关性及预测价值

目的评估凝血酶抗凝酶复合物(TAT)、血栓调节蛋白(TM)、纤溶酶-抗纤溶酶复合物(PIC)和组织型纤溶酶原激活抑制复合物(t-PAIC)与重型血液毒毒蛇咬伤中毒后弥散性血管内凝血(DIC)的临床相关性及预测价值。方法连续纳入2019年4月至2023年4月收治的重型血液毒毒蛇咬伤中毒患者作为研究对象,共132例。依据住院期间是否出现DIC分为观察组(发生DIC,n=37)及对照组(未发生DIC,n=95)。检测2组血浆TAT、TM、PIC、t-PAIC浓度。应用二元、无分类协变量的非条件Logistic回归分析TAT、TM、PIC、t-PAIC浓度与重型血液毒毒蛇咬伤中毒后DIC的临床相关性,建立受试者工作特征(ROC)曲线分析TAT、TM、PIC、t-PAIC对重型血液毒毒蛇咬伤中毒后DIC的预测能力。结果观察组TAT、TM、PIC、t-PAIC显著高于对照组(P<0.05)。二元、无分类协变量的非条件Logistic回归分析显示,TAT[OR=1.517(95%CI:1.155,1.879)]、TM[OR=1.647(95%CI:1.108,2.186)]、PIC[OR=3.989(95%CI:2.986,4.992)]、t-PAIC[OR=1.111(95%CI:0.854,1.368)]是重型血液毒毒蛇咬伤中毒患者发生DIC的危险因素(P<0.05)。ROC曲线分析显示,TAT、TM、PIC、t-PAIC是预测重型血液毒毒蛇咬伤中毒患者DIC的有效指标(P<0.05),其曲线下面积(AUC)分别为0.865(95%CI:0.790,0.939)、0.771(95%CI:0.673,0.870)、0.847(95%CI:0.804,0.889)、0.680(95%CI:0.573,0.787),联合预测效能更优异(P<0.001),AUC为0.904(95%CI:0.875,0.933)。结论TAT、TM、PIC和t-PAIC检测对判断重型血液毒毒蛇咬伤中毒患者是否发生DIC有重要参考价值,可以较好地评估患者凝血功能状态,4个指标联合预测DIC的效能更优。

动态心电图及sST2、PAI-1在川崎病伴发冠脉损伤诊断中的研究

目的探讨动态心电图及可溶性人基质裂解素-2(sST2)、纤溶酶原激活物抑制物-1(PAI-1)在川崎病伴发冠脉损伤诊断中的意义。方法研究对象选取2018年1月至2024年1月郑州大学第一附属医院收治的102例川崎病患儿,根据患儿是否伴发冠脉损伤分为两组,其中损伤组40例,未损伤组62例。比较两组患儿的临床病例资料[性别、年龄、身体质量指数(BMI)、发热持续时间、白细胞计数、25-羟维生素D3(25-(OH)D_(3))、血红蛋白、血小板计数、肌酸激酶同工酶(CK-MB)、氨基末端脑利钠肽前体(NT-proBNP)、C反应蛋白(CRP)、sST2、PAI-1]及动态心电图异常率,通过多因素分析川崎病伴发冠脉损伤的影响因素,绘制ROC曲线评价不同指标对川崎病患儿伴发冠脉损伤的诊断价值。结果损伤组患儿的发热持续时间、血小板计数、CRP、CK-MB、NT-proBNP、sST2、PAI-1水平高于未损伤组,25-(OH)D_(3)水平低于未损伤组,差异具有统计学意义(P<0.05)。损伤组患儿的动态心电图异常率为60.00%,未损伤组患儿的动态心电图异常率为16.13%,损伤组高于未损伤组,差异具有统计学意义(P<0.05)。二元Logistic分析结果显示,发热持续时间、25-(OH)D_(3)、血小板计数、CRP、CK-MB、NT-proBNP、sST2、PAI-1、动态心电图异常是川崎病患儿伴发冠脉损伤的影响因素(P<0.05)。以sST2、PAI-1、动态心电图异常及3项指标联合应用作为变量绘制诊断川崎病伴发冠脉损伤的ROC曲线,sST2的AUC为0.789,PAI-1的AUC为0.729,动态心电图异常的AUC为0.719,联合检测的AUC为0.978。结论动态心电图及sST2、PAI-1水平诊断川崎病是否伴发CAL具有较高的诊断价值。

t-PAIC、TM和血栓弹力图在溃疡性结肠炎患者活动度评估中的应用

目的探讨组织纤溶酶原激活物-抑制剂复合物(t-PAIC)、血栓调节蛋白(TM)在溃疡性结肠炎(UC)患者中的水平,以及t-PAIC、TM和血栓弹力图(TEG)评估UC患者活动度的价值。方法选取2021年2月至2023年3月在新乡市第二人民医院住院治疗的82例UC患者为试验组,按照1∶1的比例同时选取同期在新乡市第二人民医院体检的82例健康体检者作为对照组。比较试验组及对照组纤维蛋白(原)降解产物(FDP)、D-二聚体(D-D)、t-PAIC、TM水平及TEG各指标[凝血反应时间(R)、血块动力时间(K)、凝固角(Angle角)、纤维蛋白溶解率(LY30)及最大振幅(MA)]差异。根据改良Mayo评分系统对UC患者进行分组并比较不同病情各组之间FDP、D-D、t-PAIC、TM水平及TEG各指标差异。采用多因素Logistic回归分析t-PAIC、TM和TEG各指标对UC患者疾病活动指数评分的影响;采用受试者工作特征(ROC)曲线分析各指标对UC患者活动度的评估价值。结果与对照组相比,试验组血清FDP、D-D、t-PAIC、TM水平明显升高(P<0.05)。TEG检测结果显示试验组R、K明显低于对照组,Angle角、LY30及MA明显高于对照组,差异均有统计学意义(P<0.05)。根据改良Mayo评分将82例UC患者分为缓解期组8例,轻度活动组26例,中度活动组29例及重度活动组19例。UC不同病情各组间FDP、D-D、t-PAIC、TM水平及R、K、Angle角、LY30、MA比较,差异均有统计学意义(P<0.05)。多因素Logistic回归分析结果显示,t-PAIC、TM、LY30是UC患者疾病活动度的影响因素(OR=1.719、1.531、2.067,均P<0.05)。以Mayo评分<6分的UC患者为对照,绘制ROC曲线,结果显示t-PAIC、TM、LY30鉴别诊断UC患者活动度的曲线下面积(AUC)分别为0.784(95%CI:0.684~0.883)、0.738(95%CI:0.629~0.847)、0.826(95%CI:0.737~0.916)。结论t-PAIC、TM及LY30是UC患者疾病活动度的影响因素,检测t-PAIC、TM及LY30可以有效评估UC患者的活动度。

脓毒症合并心肌损伤患者血清t-PAI-C、HBP、HMGB1水平与预后的关系研究

目的 探究脓毒症合并心肌损伤患者血清组织纤溶酶原激活物-纤溶酶原激活物抑剂-1复合物(t-PAI-C)、肝素结合蛋白(HBP)、外周血高迁移率组蛋白B1(HMGB1)水平与其预后的关系。方法 回顾性分析2020年3月至2023年3月蚌埠医学院第一附属医院收治的105例脓毒症合并心肌损伤患者的临床资料,依据患者治疗后28 d存活情况将其分为存活组与死亡组。比较两组临床资料(性别、年龄、体重指数、感染部位、平均动脉压、射血分数)、血清心肌肌钙蛋白I(cTnI)、t-PAI-C、HBP、HMGB1水平以及急性生理学和慢性健康状况评价Ⅱ(APACHEⅡ)评分,分析影响脓毒症合并心肌损伤患者预后的影响因素;探究t-PAI-C、HBP、HMGB1水平与cTnI、APACHEⅡ评分的相关性;绘制受试者工作特征(ROC)曲线分析t-PAI-C、HBP、HMGB1诊断脓毒症合并心肌损伤患者预后的价值。结果 脓毒症合并心肌损伤患者随访期间出现死亡30例(28.57%),存活75例(71.43%)。死亡组患者的cTnI、t-PAI-C、HBP、HMGB1水平以及APACHEⅡ评分分别为(1.58±0.43)μg/L、(16.75±4.00)ng/mL、(45.68±9.25)ng/mL、(125.00±20.18)μg/L、(17.63±2.66)分,均高于存活组[(0.65±0.11)μg/L、(13.20±2.68)ng/mL、(38.00±8.63)ng/mL、(96.69±11.25)μg/L、(11.50±1.68)分],差异均有统计学意义(P<0.05)。cTnI、t-PAI-C、HBP、HMGB1以及APACHEⅡ评分均为影响脓毒症合并心肌损伤患者预后的独立危险因素(P<0.05)。t-PAI-C、HBP、HMGB1与cTnI、APACHEⅡ评分之间均呈正相关(P<0.05)。t-PAI-C、HBP、HMGB1三者联合诊断脓毒症合并心肌损伤患者预后的曲线下面积(AUC)为0.950(0.889~0.983),敏感度与特异度分别为83.33%和93.33%,诊断效能均优于单一的t-PAI-C、HBP、HMGB1指标(P<0.05)。结论 t-PAI-C、HBP、HMGB1水平与cTnI、APACHEⅡ评分相关性较好,可作为临床诊断脓毒症合并心肌损伤的潜在生物学标记物,三者联合预测脓毒症合并心肌损伤患者预后效能较好。

股骨颈骨折内固定术后血清学指标PAI-1作为股骨头坏死并发症风险因素的探究

目的 探究股骨颈骨折内固定术后股骨头坏死的风险因素,明确血清学指标纤溶酶原激活物抑制剂-1(PAI-1)对股骨头坏死的预测价值。方法 纳入该院2021年1月至2022年1月收治的股骨颈骨折内固定术患者95例。获取患者相关临床信息,并检测患者术前,术后1、2和3 d血清PAI-1水平;术后随访1年时间,根据患者是否发生股骨头坏死将患者分为坏死组和无坏死组;在术后1年收集所有患者视觉模拟评分(VAS)、西安大略麦克马斯特大学骨关节炎指数(WOMAC)和Harris髋关节评分(HHS)情况;比较坏死组和无坏死组患者的临床信息和术前、术后血清PAI-1水平差异,明确股骨头坏死的相关风险因素并进行Logistic回归分析;探究术后血清PAI-1水平与患者VAS、WOMAC和HHS之间的关系;绘制血清PAI-1作为股骨头坏死预测指标的受试者工作特征(ROC)曲线,明确其预测价值。结果 坏死组和无坏死组Garden分型、复位质量比较差异有统计学意义(P<0.05),坏死组术后1、2 d血清PAI-1水平均高于无坏死组(P<0.05);患者术后1、2 d血清PAI-1水平与VAS和WOMAC呈正相关(P<0.05),与HHS呈负相关(P<0.05);Logistic回归分析结果显示,术后1、2 d血清PAI-1水平升高是股骨头坏死的危险因素(P<0.05);ROC曲线结果显示,术后2 d血清PAI-1水平相较于术后1 d血清PAI-1水平预测价值更高,术后2 d血清PAI-1水平预测股骨头坏死的最佳截断值为44.8 ng/L,灵敏度为68.49%,特异度为86.36%,曲线下面积(AUC)为0.807。结论 股骨颈骨折内固定术后1、2 d血清PAI-1水平可用于预测术后股骨头坏死的发生,尤其是术后2 d血清PAI-1水平。

慢性阻塞性肺疾病急性加重期患者血清CCR5、PAI-1水平与肺功能及病情严重程度的关系

目的 探究慢性阻塞性肺疾病急性加重期(AECOPD)患者血清细胞趋化因子受体5(CCR5)、纤溶酶原激活物抑制剂-1(PAI-1)水平变化与肺功能及病情严重程度之间的关系。方法 选取该院2020年1月至2022年1月急诊收治的114例AECOPD患者为AECOPD组,并选取同期稳定期慢性阻塞性肺疾病(COPD)患者114例为对照组。采用酶联免疫吸附试验(ELISA)测定CCR5、PAI-1水平;比较AECOPD组与对照组及不同病情程度AECOPD患者血清CCR5、PAI-1水平及肺功能指标;Pearson相关性分析AECOPD患者血清CCR5、PAI-1水平与肺功能指标之间的关系;Spearman相关性分析AECOPD患者血清CCR5、PAI-1水平与病情严重程度之间的关系。结果 与对照组相比,AECOPD组患者血清CCR5、PAI-1水平均显著升高,差异均有统计学意义(P<0.05),肺功能指标:第1秒用力呼气量(FEV_(1))、FEV_(1)与用力肺活量比值(FEV_(1)/FVC)、FEV_(1)占预计值百分比(FEV_(1)%pred)、最大呼气中期流量(MMEF)占预计值百分比(MMEF%pred)均显著降低,差异有统计学意义(P<0.05),且随着病情程度的增加,血清CCR5、PAI-1水平逐渐增加(P<0.05),FEV_(1)、FEV_(1)/FVC、FEV_(1)%pred、MMEF%pred水平逐渐降低(P<0.05);Pearson相关性分析结果显示,血清CCR5、PAI-1水平与FEV_(1)、FEV_(1)/FVC、FEV_(1)%pred、MMEF%pred均呈显著负相关(P<0.05);Spearman相关性分析结果显示,AECOPD患者血清CCR5、PAI-1水平与病情程度呈显著正相关(r_(1)=0.432,r_(2)=0.451,P<0.05)。结论 AECOPD患者血清CCR5、PAI-1水平显著升高,且血清CCR5、PAI-1水平与AECOPD患者肺功能及病情程度密切相关。